



Mayo Clinic Center for Tuberculosis
Rochester Clinical Intensive
November 13-14, 2017

	ACPE UAN/ Contact Hours	Program Schedule
November 13		
7:45 – 8:15		Registration
8:15 – 8:30		Welcome and Program Overview/Pre-Test – <i>Stacey Rizza, M.D., John Wilson, M.D. & Zelalem Temesgen, M.D.</i>
8:30 – 8:45	0853-0000-17-079-L01-P/ 0.25	Epidemiology of Tuberculosis – <i>Dzung Thai, M.P.H</i> <ul style="list-style-type: none"> • Describe the TB epidemic in terms of susceptible groups • Describe major factors that will affect future trends in TB
8:45 – 9:30	0853-0000-17-080-L01-P/ 0.75	TB Pathogenesis – <i>Stacey Rizza, M.D.</i> <ul style="list-style-type: none"> • Describe the pathogenesis of <i>M. tuberculosis</i>
9:30 – 10:15	0853-0000-17-081-L01-P/ 0.75	TB Transmission & Infection Control – <i>E. Ann Misch, M.D.</i> <ul style="list-style-type: none"> • Explain how drug-resistant TB disease develops • Describe the components of an effective infection control program • Explain administrative, engineering controls, and respiratory protection
10:15 – 10:30		Break
10:30 – 11:15	0853-0000-17-082-L01-P/ 0.75	Targeting Testing and Diagnosis of LTBI Infection – <i>Jeremy Clain, M.D.</i> <ul style="list-style-type: none"> • Explain Use of TST • Explain use of IGRA testing
11:15 – 12:00	0853-0000-17-083-L01-P/ 0.75	Treatment Options for LTBI – <i>Pamela Hackert, M.D., J.D.</i> <ul style="list-style-type: none"> • Describe treatment options for LTBI • Review monitoring strategies for TB patients with co-morbid conditions • Describe monitoring recommendations for patients on LTBI treatment
12:00 – 1:15		Lunch
1:15 – 2:00	0853-0000-17-084-L01-P/ 0.75	Laboratory TB Diagnostics – <i>Nancy Wengenack, Ph.D.</i> <ul style="list-style-type: none"> • Describe laboratory methods used for the detection, identification, genotyping, and drug susceptibility testing of <i>M. tuberculosis</i>
2:00-3:00	0853-0000-17-085-L01-P/ 1.0	Radiology – <i>Dana Kissner, M.D.</i> <ul style="list-style-type: none"> • Identify the major structures on a normal chest x-ray • Identify major chest x-ray abnormalities commonly seen in TB
3:00-3:15		Break
3:15-4:00	0853-0000-17-086-L01-P/ 0.75	Interesting Cases – <i>Douglas Hornick, M.D.</i> <ul style="list-style-type: none"> • Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case.
4:00-4:15		Q&A/Post Test
4:15		Adjourn

	ACPE UAN/ Contact Hours	Program Schedule
November 14		
7:45-8:00		Sign in
8:00 – 8:15		Review / Q&A
8:15-9:00	0853-0000-17-087-L01-P/ 0.75	Treatment of TB – James Sunstrum, M.D. <ul style="list-style-type: none"> Identify the basic principles of drug resistant TB Describe the current guidelines for the treatment of TB disease including the newly released CDC guidelines
9:00 – 10:00	0853-0000-17-088-L01-P/ 1.0	TB Drug Toxicity - John Zeuli, Pharm. D. <ul style="list-style-type: none"> Describe the common adverse reactions to TB treatment regimens Explain how to manage adverse reactions to TB treatment regimens
10:00 – 10:15		Break
10:15 - 10:45	0853-0000-17-089-L01-P/ 0.5	TB and Drug Resistance – Dean Tsukayama, M.D. <ul style="list-style-type: none"> Describe factors responsible for delayed response and/or treatment failure Describe treatment and management strategies for multidrug-resistant TB
10:45 – 11:15	0853-0000-17-090-L01-P/ 0.5	TB and Biologics – Claudia Dobler, M.D., Ph.D. <ul style="list-style-type: none"> Describe concept of immunomodulatory drugs (IMiDs) and development of biologics Review TNF inhibitors Identify screening recommendations and controversies
11:15-11:45	0853-0000-17-091-L01-P/ 0.5	Case Presentation - James Sunstrum, M.D. <ul style="list-style-type: none"> Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case.
11:45-1:00		Lunch
1:00-2:00	0853-0000-17-092-L01-P/ 1.0	TB and Diabetes – Richard Brostrom, M.D. <ul style="list-style-type: none"> Describe the epidemiology of diabetes in the US Describe the impact of TB on diabetes
2:00-3:00	0853-0000-17-093-L01-P/ 1.0	Mental Health Considerations – Robert Morgan, III, M.D., Ph.D. <ul style="list-style-type: none"> Describe historical parallels between tuberculosis and mental illness Identify drug-drug interactions of concern when prescribing medications to treat tuberculosis to patients with mental illness Identify and manage challenges arising from comorbid mental illness/substance use disorders that patients may face when confronting tuberculosis treatment
2:45-3:00		Break
3:00-3:45	0853-0000-17-094-L01-P/ 0.75	Interesting TB Cases – John Wilson, M.D. <ul style="list-style-type: none"> Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case.
3:45-4:00	0853-0000-17-095-L01-P/ 0.25	Resource Review – Jennifer Curran
4:00-4:15		Final Q&A/ Post Test – Stacey Rizza, M.D.